Researchers in the UAB Department of Dermatology have published a study that highlights a potential treatment for rhabdomyosarcoma, a soft-tissue tumor type found most often in children.The research, appearing in Cancer Research, focuses on an experimental compound called CP-31398 and its ability to regulate the most common mutated gene in cancer, p53. By controlling normal or mutated p53 proteins, CP-31398 shows it can inhibit rhabdomyosarcoma growth and invasiveness, says Mohammad Athar, Ph.D. professor and vice-chair of dermatology.